| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
BZ-30 (0.15-5 μM) at a concentration of 5 μM can reduce the viral RNA level in Vero E6 cells infected with wild-type SARS-CoV-2 by ≥99% and exhibits dose-dependent antiviral activity [1]. BZ-30 (24 h) can effectively inhibit the effective replication of wild-type SARS-CoV-2 in Vero E6 cells with an IC50 of 0.65 μM [1]. BZ-30 (24 h) can be used as a broad-spectrum inhibitor of various SARS-CoV-2 variants in Vero E6 cells with IC50 values ranging from 0.51 μM (β variant) to 12.37 μM (Omicron variant) [1]. BZ-30 partially inhibited the endocytosis of SARS-CoV-2 pseudoviruses; compared with the 50% inhibition rate observed in HEK293-ACE2/TMPRSS2 cells, BZ-30 showed stronger inhibitory effects in HEK293-ACE2 cells (up to 75%) [1]. BZ-30 (0–24 h) acted on the early stages of the life cycle of wild-type SARS-CoV-2 in Vero E6 cells and inhibited viral replication when administered within 2 hours post-infection [1].
|
|---|---|
| ln Vivo |
BZ-30 (15 mg/kg; intraperitoneal injection; twice daily; starting 8 hours after infection for 4 days) reduced SARS-CoV-2 viral load by 64% and improved lung pathology in Syrian golden hamsters infected with SARS-CoV-2[1].
|
| Animal Protocol |
Animal/Disease Models:Syrian golden hamster (female, 6-8 weeks old, intranasally inoculated with 10⁵ PFU SARS-CoV-2)[1]
Doses: 15 mg/kg Route of Administration: Intraperitoneal injection; twice daily for 4 days (starting 8 hours after infection) Experimental Results: The viral load in lung tissue decreased by 0.44 TCID₅₀ log₁₀/mg lung tissue, equivalent to a 64% reduction in viral load. The lung weight/body weight ratio was significantly reduced. Body weight was comparable to the positive control group (remdesivir). The cumulative histopathological lung tissue score decreased from 14 to 3. Alveolar and epithelial cell degeneration was minimal, with only occasional focal inflammatory cell infiltration around blood vessels and bronchioles. |
| References |
| Molecular Formula |
C14H13F6N3
|
|---|---|
| Molecular Weight |
337.26
|
| CAS # |
3028405-31-1
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC1(CCC1)NC2=NC3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3N2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9651 mL | 14.8254 mL | 29.6507 mL | |
| 5 mM | 0.5930 mL | 2.9651 mL | 5.9301 mL | |
| 10 mM | 0.2965 mL | 1.4825 mL | 2.9651 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
